secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001437749-24-000822
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Zevra's NDA resubmission for arimoclomol (NPC); PDUFA date June 21, 2024
--------------------------------------------------------------------------------

- FDA deems resubmission a Class II complete response with 6-month review; PDUFA date June 21, 2024.
- FDA intends to present arimoclomol NDA for discussion at an advisory committee meeting.
- Resubmission addresses previous CRL concerns with additional trial metrics, preferred analyses, and supporting studies.
- Arimoclomol is an orally-delivered, first-in-class treatment for Niemann-Pick disease type C.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924000822/0001437749-24-000822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924000822/zvra20240107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-000822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer